Martin Reck, MD, PhD, on NSCLC: Results From Three Key Trials

Posted: Wednesday, October 4, 2017

Martin Reck, MD, PhD, of the LungenClinic, discusses study finding on fixed-duration vs continuous nivolumab in patients with advanced non-small cell lung cancer; nab-paclitaxel with or without CC-486 or durvalumab in previously treated patients with advanced NSCLC; and updated results from KEYNOTE-021 on pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.